Close Menu

NEW YORK — The US Food and Drug Administration last week granted separate Emergency Use Authorizations (EUAs) for two SARS-CoV-2 serology tests developed by BioMérieux and one being offered by Beijing Wantai Biological Pharmacy.

BioMérieux's Vidas SARS-CoV-2 IgM test is designed to detect IgM antibodies against the virus, while the company's Vidas SARS-CoV-2 IgG test detects IgG antibodies. Both tests combine a two-step sandwich enzyme immunoassay method with final fluorescence detection and use human serum and plasma specimens.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.